Capricor Therapeutics (CAPR) Operating Income (2010 - 2026)

Capricor Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$36.8 million for Q1 2026.

• In Q1 2026, Operating Income fell 47.19% year-over-year to -$36.8 million; the TTM figure through Mar 2026 stood at -$119.9 million (down 416.62% YoY), while the FY2025 annual figure was -$108.1 million, down 1172.59% from the prior year.
• Operating Income was -$36.8 million for Q1 2026 at Capricor Therapeutics, down from -$29.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $26.4 million in Q4 2024 to a low of -$36.8 million in Q1 2026.
• Historically, Operating Income has averaged -$12.2 million across 5 years, with a median of -$8.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Income jumped 2158.02% in 2024, then plunged 210.57% in 2025.
• A 5-year view of Operating Income shows it stood at -$8.1 million in 2022, then jumped by 84.12% to -$1.3 million in 2023, then surged by 2158.02% to $26.4 million in 2024, then slumped by 210.57% to -$29.2 million in 2025, then declined by 26.12% to -$36.8 million in 2026.
• The last three Operating Income figures came in at -$36.8 million (Q1 2026), -$29.2 million (Q4 2025), and -$26.3 million (Q3 2025), per Business Quant data.